Postmarketing safety monitoring data suggest that nonserious local and systemic reactions are common among adolescents who receive a SARS-CoV-2 mRNA vaccine, while reports of severe adverse events like myocarditis are rare.
Between December 2020 and mid-July of this year, nearly 9 million US adolescents aged 12 to 17 years received Pfizer-BioNTech’s COVID-19 vaccine, the only one approved for use among this age group. During that period, the CDC’s Vaccine Adverse Event Reporting System (VAERS) collected 9246 reports of postvaccination adverse events in this age group, or 1 per 1000 recipients.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kuehn BM. Adolescent Myocarditis After COVID-19 Vaccination Is Rare. JAMA. 2021;326(10):902. doi:10.1001/jama.2021.14237
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.